GlassScriptPhysician profile
Stephen D Behlmer
NPI 1194823484
$1,625.14
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,549 · 2020: $76.56.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,212.49 | 2019-2020 | |
| Abbvie INC. | $219.58 | 2019-2020 | |
| Celgene Corporation | $79.59 | 2019 | |
| Janssen Biotech, INC. | $53.81 | 2019 | |
| Ucb, INC. | $17.65 | 2019 | |
| Galderma Laboratories, L.P. | $17.43 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.35 | 2019 | |
| Dusa Pharmaceuticals, INC. | $11.24 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Behlmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.